Drug-disease interactions: narrative review of aspirin in gastric ulcer

References

• Hussar DA. Drug interactions. Merck Manual; 2013 [cited 2015 Apr 21]. Available from: http://www.merckmanuals.com/home/drugs/factors-affecting-response-to-drugs/drug-interactions.
   Google Scholar
• Lindblad CI, Hanlon JT, Gross CR, et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 2006;28:1133–1143.
   PubMed Web of Science ®Google Scholar
• Dumbreck S, Flynn A, Nairn M, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350:h949. doi:10.1136/bmj.h949.
   PubMed Web of Science ®Google Scholar
• Wami WM, Buntinx F, Bartholomeeusen S, et al. Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice. Br J Gen Pract. 2013;63:e267–e273.
   PubMed Web of Science ®Google Scholar
• Buriachkovskaia LI, Uchitel IA, Sumarokov AV, et al. Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice. Ter Arkh. 2009;81:41–47.
   PubMed Web of Science ®Google Scholar
• Arakawa T, Watanabe T, Tanigawa T, et al. Quality of ulcer healing in gastrointestinal tract: its pathophysiology and clinical relevance. World J Gastroenterol. 2012;18:4811–422.
   PubMed Web of Science ®Google Scholar
• de Abajo F, Rodríguez LG. The continuing unacceptable marketing of Alka-Seltzer containing aspirin for stomach-related disorders. Drug Saf. 2009;32:619–621.
   PubMed Web of Science ®Google Scholar
• Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:175–189.
   PubMed Web of Science ®Google Scholar
• Lecchi M, D’Alonzo L, Negro A, et al. Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. Expert Opin Drug Metab Toxicol. 2014;10:1381–1395.
   PubMed Web of Science ®Google Scholar
• Kanani K, Gatoulis SC, Voelker M. Influence of differing analgesic formulations of aspirin on pharmacokinetic parameters. Pharmaceutics. 2015;7:188–198.
   PubMedGoogle Scholar
• Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 1989;86:449–458.
   PubMed Web of Science ®Google Scholar
• Ganjehei L, Becker RC. Aspirin dosing in cardiovascular disease prevention and management: an update. J Thromb Thrombolysis. 2015;40:499–511.
   PubMed Web of Science ®Google Scholar
• Gao XR, Adhikari CM, Peng LY, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol. 2009;61:1505–1510.
   PubMed Web of Science ®Google Scholar
• Harvard University. New guidelines refine aspirin prescription. Harvard Heart Newsletter; 2009 [cited 2015 Jan 31]. Available from: https://www.health.harvard.edu/newsletters/Harvard_Heart_Letter/2009/June/New-guidelines-refine-aspirin-prescription.
   Google Scholar
• Piazza G, Goldhaber SZ, Kroll A, et al. Venous thromboembolism in patients with diabetes mellitus. Am J Med. 2012;125:709–716.
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Riis A, Christensen S, et al. Diabetes and 30-day mortality from peptic ulcer bleeding and perforation: a Danish population-based cohort study. Diabetes Care. 2006;29:805–810.
   PubMed Web of Science ®Google Scholar
• Enani MA, Alharthi BN, Dewanjee N, et al. Spontaneous gastric ulcer perforation and acute spleen infarction caused by invasive gastric and splenic mucormycosis. J Glob Infect Dis. 2014;6:122–124.
   PubMedGoogle Scholar
• Levy G. Clinical pharmacokinetics of aspirin. Pediatrics. 1978;62:867–872.
   PubMed Web of Science ®Google Scholar
• Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 1985;10:164–177.
   PubMed Web of Science ®Google Scholar
• Dalvi SS, Gupta KC, Pohujani SM, et al. Bioavailability of aspirin after oral and rectal administration in volunteers and patients with fever. J Postgrad Med. 1985;31:192–195.
   PubMedGoogle Scholar
• Mojaverian P, Rocci ML, Conner DP, et al. Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. Clin Pharmacol Ther. 1987;41:11–17.
   PubMed Web of Science ®Google Scholar
• Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc. 2014;7:137–146.
   PubMedGoogle Scholar
• Hollander D, Dadufalza VD, Fairchild PA. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med. 1981;98:591–598.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Rumble RH, Wanwimolruk S, et al. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol. 1983;25:253–261.
   PubMed Web of Science ®Google Scholar
• Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218.
   PubMed Web of Science ®Google Scholar
• Patrick J, Dillaha L, Armas D, et al. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med. 2015;127:573–580.
   PubMed Web of Science ®Google Scholar
• Kapłon-Cieślicka A, Rosiak M, Postuła M, et al. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol. 2013;71:893–902.
   PubMed Web of Science ®Google Scholar
• Wood PH, Dixon AS. “Alka-seltzer” and haematemesis. Br Med J. 1963;1:328–329.
   PubMedGoogle Scholar
• Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol. 1999;84:404–409.
   PubMed Web of Science ®Google Scholar
• Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37:2153–2158.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Hawthorne AB, Hudson N, et al. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach. Clin Sci (Lond). 1991;81:565–573.
   PubMed Web of Science ®Google Scholar
• Hennerici MG, Meairs S. Aspirin dosage for prevention of cerebral infarct: arguments for low dosage. Nervenarzt. 1995;66:890–894; discussion 885.
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.
   PubMed Web of Science ®Google Scholar
• Aditi A, Graham DY, Vitamin C. Gastritis, and gastric disease: a historical review and update. Dig Dis Sci. 2012;57:2504–2515.
   PubMed Web of Science ®Google Scholar
• Cohen S. Gastritis. Merck Manual; 2006 October [cited 2015 Apr 22]. Available from: https://www.merckmanuals.com/home/digestive-disorders/peptic-disorders/gastritis.
   Google Scholar
• Uemura N, Sugano K, Hiraishi H, et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. 2014;49:814–824.
   PubMed Web of Science ®Google Scholar
• Katayama S, Inaba M, Maruno Y, et al. Increased thromboxane B2 excretion in diabetes mellitus. J Lab Clin Med. 1987;109:711–717.
   PubMed Web of Science ®Google Scholar
• Awad AS, Webb RL, Carey RM, et al. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. Am J Hypertens. 2005;18:544–548.
   PubMed Web of Science ®Google Scholar
• Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127:395–402.
   PubMed Web of Science ®Google Scholar
• Iijima K, Shimosegawa T. Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury. World J Gastroenterol. 2015;21:7709–7717.
   PubMed Web of Science ®Google Scholar
• van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol. 2008;6:309–313.
   PubMed Web of Science ®Google Scholar
• Przyklenk K. Efficacy of cardioprotective ‘conditioning’ strategies in aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging. 2011;28:331–343.
   PubMed Web of Science ®Google Scholar
• Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol. 2009;54:163–168.
   PubMed Web of Science ®Google Scholar
• Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418–458.
   PubMed Web of Science ®Google Scholar